Individual
ESR projects

Research project

Phenotypic heterogeneity of myelodysplastic cells and influence of epigenetic therapies (WP1)

Rationale and objectives

The project aims to:

1) determine the cellular mode of action of IDHis in myelodysplastic syndromes (MDS) in monotherapy or in combination with Azacitidine;

2) identify at the single-cell level the gene expression signatures associated with resistance to IDHis as monotherapy or in combination with Azacitidine;

3) identify in vitro and then validate in vivo therapeutic combinations reverting the expression of resistance signatures to IDHis.

Envisioned secondments

GenomeScan B.V. (The Netherlands, 2 months), University of Bergen (Norway, 2 months), Institute for Tumor Biology and Experimental Therapy Georg-Speyer-Haus (Germany).

PhD programme

PhD program in Hematology, University of Paris (France), Doctoral School in Hematology-Oncogenesis-Biotherapies.